Literature DB >> 7632446

Characteristics of persons with late AIDS diagnosis in the United States.

D J Hu1, R Byers, P L Fleming, J W Ward.   

Abstract

To describe characteristics of persons with late (at or after death) acquired immunodeficiency syndrome (AIDS) diagnosis, we analyzed national surveillance data among all persons with AIDS diagnosed through December 1991 under the pre-1993 AIDS case definition and with a known date of death. Late diagnosis was present in 15.8% of 163,202 decreased persons with AIDS and in 15.3% of decreased men with AIDS, 20.6% of women, 12.1% of whites, 20.0% of blacks, 21.1% of Hispanics, 12.3% of men who have sex with men (MSM), 21.9% of injecting drug users (IDU), and 19.6% of persons exposed to human immunodeficiency virus (HIV) through heterosexual contact. When age, race/ethnicity, sex, geographic region, and transmission mode were included in logistic regression analyses, among adults/adolescents, late diagnosis was more likely among persons 40 years or older than among those 13-39 years old, among blacks and Hispanics than among whites, and among IDU and persons exposed to HIV through heterosexual contact than among MSM. Although children (less than 13 years of age) were more likely to have late diagnosis than adults and adolescents, late diagnoses among children did not differ significantly by race/ethnicity, sex, geographic region, or transmission mode. Late AIDS diagnosis, especially among ethnic minorities and IDU and their sex partners, may represent delays in HIV diagnosis and care. In addition to not receiving early clinical intervention, persons who are diagnosed later in the course of HIV disease represent missed opportunities for receiving prevention efforts such as education, counseling, and substance abuse treatment.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1995        PMID: 7632446

Source DB:  PubMed          Journal:  Am J Prev Med        ISSN: 0749-3797            Impact factor:   5.043


  8 in total

1.  Estimating the prevalence of injection drug users in the U.S. and in large U.S. metropolitan areas from 1992 to 2002.

Authors:  Joanne E Brady; Samuel R Friedman; Hannah L F Cooper; Peter L Flom; Barbara Tempalski; Karla Gostnell
Journal:  J Urban Health       Date:  2008-03-15       Impact factor: 3.671

2.  HIV and the black community: the role of the National Medical Association.

Authors:  M K Rawlings; R Lewis
Journal:  J Natl Med Assoc       Date:  1997-10       Impact factor: 1.798

Review 3.  The adolescent and young adult HIV cascade of care in the United States: exaggerated health disparities.

Authors:  Brian C Zanoni; Kenneth H Mayer
Journal:  AIDS Patient Care STDS       Date:  2014-03       Impact factor: 5.078

Review 4.  Linkage to care for HIV-infected heterosexual men in the United States.

Authors:  Nickolas D Zaller; Jeannia J Fu; Amy Nunn; Curt G Beckwith
Journal:  Clin Infect Dis       Date:  2011-01-15       Impact factor: 9.079

5.  Access to antiretroviral treatment among French HIV infected injection drug users: the influence of continued drug use. MANIF 2000 Study Group.

Authors:  M P Carrieri; J P Moatti; D Vlahov; Y Obadia; C Reynaud-Maurupt; M Chesney
Journal:  J Epidemiol Community Health       Date:  1999-01       Impact factor: 3.710

6.  Acceptance of and barriers to voluntary HIV counselling and testing among adults in Guizhou province, China.

Authors:  Wei Ma; Roger Detels; Yuji Feng; Zunyou Wu; Limei Shen; Yu Li; Zezhen Li; Fang Chen; Aimin Wang; Taiming Liu
Journal:  AIDS       Date:  2007-12       Impact factor: 4.177

7.  The prevalence of people who inject drugs among those with HIV late presentation: a meta-analysis.

Authors:  Negin Farhadian; Behzad Karami Matin; Vahid Farnia; Mohammad Hossein Zamanian; Farid Najafi; Maryam Farhadian
Journal:  Subst Abuse Treat Prev Policy       Date:  2022-02-10

8.  Contributions to early HIV diagnosis among patients linked to care vary by testing venue.

Authors:  Michael S Lyons; Christopher J Lindsell; Deanna A Hawkins; Dana L Raab; Alexander T Trott; Carl J Fichtenbaum
Journal:  BMC Public Health       Date:  2008-06-25       Impact factor: 3.295

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.